Clinical Trials

TROPICS-02 for HR+/HER2- Metastatic Breast Cancer

Immunomedics is launching a registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease. For more information, please visit

ASCENT Trial for Metastatic Triple-Negative Breast Cancer

Immunomedics is currently sponsoring an international Phase 3 clinical trial of sacituzumab govitecan in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease. For more information on this clinical trial, please visit

TROPHY U-01 for Metastatic Urothelial Cancer

Immunomedics is recruiting for a Phase II trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies.  For more information visit

Compassionate Use Program

Immunomedics does not have a Compassionate Use Program for IMMU-132 at this time; however, patients with refractory/relapsed triple-negative breast cancer may be eligible for enrollment in the large ASCENT clinical trial ( Identifier: NCT02574455). Subjects are currently being recruited at 177 locations in the United States and Europe.